Cargando…

Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial

BACKGROUND: The effectiveness and safety of Huashibaidu granule (HSBD) in treating mild Corona Virus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. METHODS: A prospective, non-randomized, co...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Bowu, Xue, Yan, Jing, Hua, Wang, Xiaodong, Zhu, Peimin, Hao, Weiwei, Li, Man, Gao, Yueqiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121152/
https://www.ncbi.nlm.nih.gov/pubmed/37192979
http://dx.doi.org/10.1016/j.imr.2023.100950
_version_ 1785029321850617856
author Chen, Bowu
Xue, Yan
Jing, Hua
Wang, Xiaodong
Zhu, Peimin
Hao, Weiwei
Li, Man
Gao, Yueqiu
author_facet Chen, Bowu
Xue, Yan
Jing, Hua
Wang, Xiaodong
Zhu, Peimin
Hao, Weiwei
Li, Man
Gao, Yueqiu
author_sort Chen, Bowu
collection PubMed
description BACKGROUND: The effectiveness and safety of Huashibaidu granule (HSBD) in treating mild Corona Virus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. METHODS: A prospective, non-randomized, controlled study in mild COVID-19 patients was conducted in Shanghai, from April 8 to May 6, 2022. The enrolled patients were diagnosed as mild COVID-19. Finally, 360 patients received HSBD, and 368 patients received TCM placebo (administered orally 20 g twice daily for 7 days). The primary endpoints were the negative conversion rate of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the negative conversion time. Secondary endpoints included the hospitalized days and the improvement in the clinical condition. RESULTS: The negative conversion rate of SARS-CoV-2 at 7 days posttreatment in the HSBD group was higher than that in the control group (95.28% vs. 82.61%, P < 0.001). The median negative conversion time in the HSBD group was markedly decreased by 2 days compared with the control group (3 [3–6] vs. 5 [4–7], P < 0.001). In addition, the median hospitalized day was shortened in the HSBD group by 1 day compared with the control group (6 [4–7] vs. 7 [5–9], P < 0.001). The clinical improvement rate (275/360 [76.39%]) in the HSBD group within 7 days was significantly higher than that (203/368 [55.16%]) in the control group (P < 0.001). The improvement of symptom scores in the HSBD group was higher than that in the control group (2 [1–4] vs. 1 [1–2], P < 0.001). No severe adverse events occurred. CONCLUSIONS: Our study suggested that HSBD effectively increased the negative conversion rate of SARS-CoV-2 and shortened the negative conversion time and hospitalized days in mild COVID-19 patients. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2200058668
format Online
Article
Text
id pubmed-10121152
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-101211522023-04-24 Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial Chen, Bowu Xue, Yan Jing, Hua Wang, Xiaodong Zhu, Peimin Hao, Weiwei Li, Man Gao, Yueqiu Integr Med Res Original Article BACKGROUND: The effectiveness and safety of Huashibaidu granule (HSBD) in treating mild Corona Virus Disease 2019 (COVID-19) patients infected with SARS-CoV-2 remain to be identified. We aimed to evaluate the effectiveness of HSBD in mild COVID-19 patients. METHODS: A prospective, non-randomized, controlled study in mild COVID-19 patients was conducted in Shanghai, from April 8 to May 6, 2022. The enrolled patients were diagnosed as mild COVID-19. Finally, 360 patients received HSBD, and 368 patients received TCM placebo (administered orally 20 g twice daily for 7 days). The primary endpoints were the negative conversion rate of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and the negative conversion time. Secondary endpoints included the hospitalized days and the improvement in the clinical condition. RESULTS: The negative conversion rate of SARS-CoV-2 at 7 days posttreatment in the HSBD group was higher than that in the control group (95.28% vs. 82.61%, P < 0.001). The median negative conversion time in the HSBD group was markedly decreased by 2 days compared with the control group (3 [3–6] vs. 5 [4–7], P < 0.001). In addition, the median hospitalized day was shortened in the HSBD group by 1 day compared with the control group (6 [4–7] vs. 7 [5–9], P < 0.001). The clinical improvement rate (275/360 [76.39%]) in the HSBD group within 7 days was significantly higher than that (203/368 [55.16%]) in the control group (P < 0.001). The improvement of symptom scores in the HSBD group was higher than that in the control group (2 [1–4] vs. 1 [1–2], P < 0.001). No severe adverse events occurred. CONCLUSIONS: Our study suggested that HSBD effectively increased the negative conversion rate of SARS-CoV-2 and shortened the negative conversion time and hospitalized days in mild COVID-19 patients. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2200058668 Elsevier 2023-06 2023-04-21 /pmc/articles/PMC10121152/ /pubmed/37192979 http://dx.doi.org/10.1016/j.imr.2023.100950 Text en © 2023 Korea Institute of Oriental Medicine. Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Chen, Bowu
Xue, Yan
Jing, Hua
Wang, Xiaodong
Zhu, Peimin
Hao, Weiwei
Li, Man
Gao, Yueqiu
Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
title Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
title_full Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
title_fullStr Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
title_full_unstemmed Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
title_short Effectiveness of Chinese medicine formula Huashibaidu granule on mild COVID-19 patients: A prospective, non-randomized, controlled trial
title_sort effectiveness of chinese medicine formula huashibaidu granule on mild covid-19 patients: a prospective, non-randomized, controlled trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121152/
https://www.ncbi.nlm.nih.gov/pubmed/37192979
http://dx.doi.org/10.1016/j.imr.2023.100950
work_keys_str_mv AT chenbowu effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial
AT xueyan effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial
AT jinghua effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial
AT wangxiaodong effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial
AT zhupeimin effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial
AT haoweiwei effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial
AT liman effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial
AT gaoyueqiu effectivenessofchinesemedicineformulahuashibaidugranuleonmildcovid19patientsaprospectivenonrandomizedcontrolledtrial